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 Abstract 
 Growth hormone (GH) is the most frequently used treatment 
in children with idiopathic short stature (ISS). Aromatase 
inhibitor (AI) therapy is still in an experimental state, and both 
fi nal height (FH) and long-term effi cacy data in ISS have not 
been published. We present a 14.5-year-old boy with ISS and 
a height of 142.7 cm [standard deviation score (SDS)  – 2.79]. 
Based on the baseline bone age (BA) of 13.5 – 14 years, his 
predicted adult height (PAH) by Bayley/Pinneau was 154 
cm (SDS  – 3.77) – 158.2 (SDS  – 3.15). After a 5-year letrozole 
monotherapy, FH was 169 cm (SDS  – 1.57) showing a height 
difference between PAH and FH from 10.8 to 15 cm. No per-
manent side effects of the medication have been observed. 
Both a transient occurrence and a spontaneous recovery of 
decreased bone mineral apparent density were seen, veri-
fi ed by dual-energy X-ray absorptiometry. Spinal magnetic 
resonance imaging revealed no vertebral abnormalities. AI 
therapy might be an effective and low-cost alternative to the 
use of GH. Further controlled trials should prove effi cacy and 
safety of long-term AI therapy in boys with ISS. 
 Keywords:  fi nal adult height;  idiopathic short stature;  long-
term aromatase inhibition;  safety aspects. 
 Introduction 
 The diagnosis of idiopathic short stature (ISS) requires an 
individual height of at least  – 2 standard deviation score 
(SDS) below the population mean for age and sex, and 
the absence of growth-related underlying diseases, such 
as endocrine disorders, malnutrition, chronic systemic dis-
eases, or genetic defects (i.e., haploinsuffi ciency of the short 
stature homeobox-containing gene SHOX)  (1) . Concomitant 
counseling of children with ISS is recommended if they 
suffer from stigmatization, social isolation, chronic psy-
chosocial stress, and their restricted quality of life  (2) . The 
importance of impairments related to short stature later in 
life is supported by a population-based study investigat-
ing the association between height and the risk of suicide 
in more than one million Swedish men. It could be shown 
that an increase in height of 5 cm was associated with a 9 % 
decrease in suicide risk  (3) . Although psychosocial effects 
of short stature do not generally result in clinically signifi -
cant problems of psychosocial adaptation, some patients 
suffer from it and consult frequently pediatric endocrinolo-
gists  (2) . Growth hormone (GH) is the most frequently used 
medical treatment in children with ISS, which was approved 
in the United States by the Food and Drug Administration 
(FDA) in 2003  (1, 2) , but the European Medicines Agency 
(EMEA) has not been given an approval for GH in ISS so 
far. The alternative aromatase inhibitor (AI) therapy, which 
has been shown to be effective in increasing predicted adult 
height (PAH) in children with ISS, is still at the experimen-
tal stage  (4) . However, the costs of treatment are consider-
ably lower administering an AI than GH. The treatment with 
GH in children with ISS has resulted in a mean increase in 
adult height of 3.5 – 7.5 cm during a 4- to 10-year period of 
treatment  (1) . Previous treatment with the AI letrozole for 
2 years has led to a PAH increase of 5.9 cm in boys with ISS 
 (4) . The main reasons for describing the case of a boy with 
ISS are a safe long-term letrozole monotherapy over 5 years 
resulting in a 10.8- to 15-cm height difference between PAH 
and fi nal height (FH) and the reversibility of decreased bone 
mineral apparent density (BMAD) 3 years after fi nishing the 
letrozole therapy. 
 Patient report 
 The 14.5-year-old boy was referred to pediatric endocrine 
evaluation because of severe short stature. There was no fam-
ily history of endocrine or bone diseases. The mother was 
measured at 155 cm (SDS  – 1.87), and the father ’ s height was 
167 cm (SDS  – 2.01). The boy was born after 40 weeks of 
normal pregnancy and delivery to healthy, non-consanguineous 
parents with a birth weight of 3315 g (SDS  – 0.58) and a 
length of 49 cm (SDS  – 0.92). At initial presentation, the 
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patient had a height of 142.7 cm ( – 2.79 SDS) and a weight 
of 38.7 kg, for a body mass index of 19 kg/m 2 (50th percen-
tile for age and gender). His genetic target height by Tanner 
 (5) was 167.5 cm (SDS  – 1.79), calculated by the equation: 
(father ’ s height + mother ’ s height)/2 ± 6.5 cm. He was propor-
tionate, had no dysmorphic features, and was pubertal, with 
Tanner stage 2 as to pubic hair and genital development. His 
testicular volume was 5 mL. Estimated bone age (BA) was 
13.5 – 14 years by Greulich/Pyle method. Therefore, PAH by 
Bayley/Pinneau method  (6) was154 cm (SDS  – 3.77) to 158.2 
cm (SDS  – 3.15). Laboratory analyses including hepatic, 
renal, and endocrine function, sweat test, and celiac disease 
markers were normal. 
 Results 
 Growth 
 Treatment with the AI letrozole (Femara, Novartis AG, 
Switzerland) at a dose of 2.5 mg daily was administered for 5 
years. Based on the baseline BA of 13.5 – 14 years, the differ-
ence between PAH of 154 (SDS  – 3.77) to 158.2 (SDS  – 3.15) 
cm at the beginning and FH of 169 cm (SDS  – 1.57) at the end 
of the letrozole therapy was10.8 – 15 cm. FH was defi ned as 
height at an age  ≥ 22 years or height velocity  ≤ 0.5 cm in the 
foregoing year. The height velocity during the 5-year follow-up 























 Figure 1  Growth chart (A) and X-ray pictures of the left hand (B, C) of a boy with ISS who was treated with letrozole (Femara, Novartis AG, 
Switzerland) at a dose of 2.5 mg daily over a period of 5 years. Before treatment, the boy ’ s height was 142.7 cm (SDS  – 2.79), his bone age 
according to Greulich/Pyle 13.5–14 years (Figure 1B), and his predicted adult height according to Bayley/Pinneau was 154 cm (SDS  – 3.77). 
Long-term letrozole treatment resulted in a fi nal adult height of 169 cm (SDS  – 1.57). At the end of the letrozole treatment, the bone age accord-
ing to Greulich/Pyle was 16 years (Figure 1C). The corresponding bone age values are shown as black rhombuses. P, percentile; L, left hand; 
SDS, standard deviation score. 
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adverse effect. The progression of puberty was slightly accel-
erated with normal pubertal maturation. Tanner stage assess-
ments of pubic hair and genital development were performed 
at least once a year. The boy had Tanner stage development 2 
aged 14.5 (initiation of letrozole therapy), stage 4 aged 15.3, 
stage 5 aged between 15.9 and 19.5 (discontinuation of letro-
zole therapy). Testicular volume was 5 mL aged 14.5 (initia-
tion of letrozole therapy), 15 mL aged 15.3, 20 mL aged 16.9, 
and 25 mL aged 19.5 (discontinuation of letrozole therapy). 
 Laboratory determinations 
 The patient was particularly monitored for endocrine, hepatic, 
and renal functions and showed no signifi cant modifi cation 
(Table  1 ). 
 Radiological fi ndings 
 Repeated hand X-rays were performed and revealed an esti-
mated BA by Greulich/Pyle method of 13.5 – 14 years at a 
chronological age of 14.5 years and a BA of 16 years at the 
end of the 5-year treatment period when the patient was 19.5 
years old (see Figure 1). Hand bones showed no signs of 
demineralization or fractures. BA determinations were per-
formed by two independent pediatric radiologists (O.M-E, 
M.U.). 
 In addition, spinal magnetic resonance imaging (MRI) 
of the patient was performed using a 1.5-Tesla Imager 
(MR-Avanto, Siemens Medical Systems, Erlangen, 
Germany) in two steps. First, the imaging protocol of 
the cervical and upper thoracic spine. Second, the imag-
ing protocol of the lower thoracic and lumbosacral spine. 
The composed sequences with 11 sagittal slices were per-
formed with T1-weighted (fi eld of view (FOV) 679 × 379 
mm, slice thickness 3 mm, gap 10 % = 0.3 mm, acquisition 
matrix 416 × 746 mm) and T2-weighted (FOV 681 × 379 
mm, slice thickness 3 mm, gap 10 % = 0.3 mm, acquisi-
tion matrix 486 × 872 mm) images. All protocols consisted 
of turbo-spin echo sequences for the assessment of verte-
bral anatomy, endplate abnormalities, and intervertebral 
disk. The MRI images were visually analyzed for verte-
bral anatomy and shape, endplate changes, disk height and 
water content, and muscle status of the back by a radiolo-
gist (OM-E). Measurements of vertebral body dimensions 
and assessments of the shape of each vertebral body were 
performed with a digital caliper in the radiologic worksta-
tion. Our patient showed no abnormalities in spinal MRI 
(Figure  2 ). The shapes of all vertebral bodies were classi-
fi ed as normal using the classifi cation for pediatric vertebral 
body morphology  (7) . 
 Bone mineral apparent density (BMAD ) 
 After discontinuation of letrozole treatment, examination of 
BMAD (8) with dual-energy X-ray absorptiometry (DXA) 
scanning (Lunar Prodigy Advance, GE Lunar Corp, Madison, 
 Table 1  Blood values prior, under, and after a 5-year treatment with the AI letrozole in a boy with idiopathic short stature. 
Parameter Letrozole treatment Reference values
Prior Under After
Age, years 14.5  19.5
Testosterone, nmol/L a 2.4  36.9  18.7
 12.2 – 41.6  Adults
 0.7 – 10.4  Adolescents
LH, IU/L 0.94  4.23  2.70  1.7 – 8.6
FSH, IU/L 1.0  3.0  1.30  1.5 – 12.4
Estradiol, pmol/L b 58.7 139.5 136.1
 27.9 – 191  Adults
Cortisol, nmol/L, a.m. 226.2 146.2 446.9 171.0 – 535.2
TSH, mIU/L 1.12  1.22  1.84  0.27 – 4.20
AP, U/l 237 138  91  40 – 129
IGF-I, nmol/L  –  –  35.5  15.2 – 46.9
Inhibin B, ng/L  –  – 363 120 – 400
25-OH-vitamin D, nmol/L  –  –  58.5  50 – 175
Creatinine,  μ mol/L 72.6  81.4  91.2  74.3 – 110.6
γ-GT, U/L 20  22  20  < 60
ALT, U/L  18  25  18  < 45
Triglycerides, mmol/L  –  –  1.02  0.29 – 2.28
TC, mmol/L  –  –  5.47  3.1 – 6.2
LDL-C, mmol/L  –  –  3.23  1.29 – 4.0
HDL-C, mmol/L  –  –  1.37  1.03 – 2.06
Hematocrit,  %  41  44  46  33 – 61
Hemoglobin, mmol/L  9.0  10.0  10.1  8.1 – 9.9
 
a
 Chiron Diagnostics ACS: 180T testosterone test, Chiron Diagnostics GmbH, D-35465 Fernwald, Germany.  b Chiron Diagnostics ACS: 180 
 Ö stradiol-6 II test. LH, luteinizing hormone; FSH, follicle-stimulating hormone; TSH, thyroid-stimulating hormone; AP, alkaline phosphatase; 
γ-GT, gamma glutamyltransferase; ALT, alanine aminotransferase; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, 
high-density lipoprotein cholesterol. 
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WI, USA) was carried out investigating the 2nd–4th vertebrae 
of the lumbar spine and the femoral neck. BMAD of the spine 
was 0.144 g/cm 3 (T-score:  – 0.84) and of the femoral neck 0.146 
g/cm 3 (T-score:  – 0.89). After a 3-year ambulatory care without 
any medication, the bone mineral content values returned to 
normal, and BMAD of the spine was 0.168 g/cm 3 (T-score: 
0.37) and of the femoral neck 0.174 g/cm 3 (T-score: 0.11). 
 Discussion 
 Based on the BA of 13.5 – 14 years, the present casuistics 
describes a height difference from 10.8 to15 cm between PAH 
and an FH after a 5-year AI monotherapy with letrozole in a 
pubertal boy with ISS. To date, AI therapy is still at the exper-
imental stage  (4) , and no long-term effi cacy and adult height 
data in males with ISS have been published. An improvement 
in PAH by 5.9 cm during a 2-year treatment with letrozole 
(2.5 mg, once daily) in 31 boys with ISS, aged 9.0 – 14.5 years, 
could be shown in a placebo-controlled Finnish study  (9) . 
Therefore, our case report might be a helpful hint indicating 
the possibility of increasing FH in males with ISS by long-
term AI therapy. 
 In comparison with GH monotherapy up to 10 years, AI 
monotherapy might not only be equally effective in increas-
ing PAH and adult height in boys with ISS but also a low-
cost alternative  (1, 4, 9) . Future well-controlled studies in 
children with ISS should involve long-term AI treatment 
with regard to adult height outcome and safety. In terms 
of AI therapy, some potential safety concerns exist. High-
density lipoprotein cholesterol could decrease, but suffi cient 
data are still lacking regarding the infl uence of aromatase 
inhibition on spermatogenesis, cognitive function, vascular 
wall function, and prostate growth  (4) . Short-term AI ther-
apy in ISS has proved to be well tolerated, but the number 
of patients who are treated within clinical trials is small  (1, 
4, 9) . In patients who may receive long-term AI therapy, 
bone health is of particular interest. AI treatment prevents 
biosynthesis of estrogen, thereby slowing its effi cacy on 
skeletal maturation, especially epiphyseal closure and bone 
mineralization  (1, 4) . Transiently reduced BMAD after a 
5-year letrozole therapy in our adolescent boy may support 
the importance of monitoring bone health during AI therapy. 
But the spontaneous recovery also shows that no permanent 
harm is to be expected. Hero et al. reported mild vertebral 
body deformities in the thoracic spine (MRI) in 5 of 11 boys 
with ISS (mean age 10.7 years) who received letrozole for 2 
years during prepuberty or early puberty  (10) . The authors 
discussed the possibility that the use of AI treatment during 
prepuberty may be associated with an increased risk of ver-
tebral deformities. Although our patient was during midpu-
berty and 4 years older than the boys with ISS described by 
Hero et al., we carefully assessed his vertebral morphology 
by spine MR imaging, but no abnormalities could be found. 
In adolescent males with GH defi ciency, an increase in adult 
height potential was seen by adding an AI to GH therapy. 
Normal pubertal progression and bone health were found 
after 2 – 3 years with this combination therapy  (11) . Another 
A B
 Figure 2  MR images of a 22.4-year-old man with ISS 3 years after the discontinuation of long-term letrozole treatment over 5 years. Sagittal 
T1-weighted MRI (A) of a composed spinal image and sagittal T2-weighted MRI (B) of a composed spinal image show normal vertebrae and 
intervertebral discs without any sign of vertebral abnormalities. 
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randomized, placebo-controlled study could show that boys 
with constitutional delay of puberty who received the AI 
letrozole in combination with low-dose testosterone reached 
a higher mean near-fi nal height than boys on testosterone 
monotherapy  (12) . Considering the positive effects of GH 
on BMD, the use of GH, together with an AI, might also be 
a treatment option in adolescents with ISS. 
 In conclusion, this case involves a 14.5-year-old boy with 
ISS who achieved a height increase between PAH and FH 
from 10.8 to 15 cm during a 5-year AI therapy. In addition, 
the boy showed both a transient occurrence and a spontane-
ous recovery of decreased BMAD after long-term AI therapy, 
verifi ed by DXA. MRI revealed no vertebral morphology 
abnormalities. Any other measures regarding health and 
safety monitoring showed no pathology. Therefore, AI ther-
apy might be an effective and low-cost alternative to the use 
of GH. However, these fi ndings deserve further attention, and 
controlled long-term studies are necessary to prove safety and 
effi cacy of AI treatment in males with ISS. 
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